Vivian Tamietti Martins

Vivian Tamietti Martins

Post-Doctoral fellow

Federal University of Minas Gerais, Brazil

Tel: +5531 98496-1567 

Email: viviantamietti@yahoo.com.br 

 

 

 

VALIDATE Role:

Network Associate

 

Research Keywords: 

Leishmaniasis, Animal Models, Clinical trials, Vaccines

 

Biography:

Graduated in Biological Sciences (2009). Master's and Ph.D degree in Biochemistry and Immunology (2016). Post-doctoral fellow in the Health Sciences Program: Infectious Diseases and Tropical Medicine (2017). Post-doctoral fellow in the Microbiology, Immunology and Infectious Diseases Program (2018). Specialist in the field of Molecular Biology; Immunology, Biotechnology and Parasitology, focusing on Diagnosis, Treatment and Vaccines for Leishmaniasis. 

 

Related Websites: 

Federal University of Minas Gerais

 

Key Publications:

Vivian Tamietti Martins et al. A recombinant fusion protein displaying murine and human MHC class I- and IIspecific epitopes protects against Leishmania amazonensis infection. Cellular Immunology. (2017). 

Vivian Tamietti Martins et al. A recombinant chimeric protein composed by human and mice-specific CD4+ and CD8+ T cell epitopes protects against visceral leishmaniasis. Parasite Immunol. (2017). 
Vivian Tamietti Martins et al. Cross-protective efficacy from an immunogen firstly identified in Leishmania infantum against tegumentary leishmaniasis. Parasite Immunol. v. 38, p.108-17 (2016). 

Vivian Tamietti Martins et al. A new Leishmania-specific hypothetical protein, LiHyT, used as a vaccine antigen against visceral leishmaniasis. Acta Trop. v. 154, p. 73-81 (2016). 

Vivian Tamietti Martins et al. Antigenicity, immunogenicity and protective efficacy of three proteins expressed in the promastigote and amastigote stages of Leishmania infantum against visceral leishmaniasis. Plos One. v. 10, p. e0137683 (2015).  
 
Vivian Tamietti Martins et al. A Leishmania-specific hypothetical protein expressed in both promastigote and amastigote stages of Leishmania infantum employed for the serodiagnosis of, and as a vaccine candidate against, visceral leishmaniasis. Parasite & Vectors. v.8, p.1-12. (2015). 
 
Vivian Tamietti Martins et al. Antigenicity and protective efficacy of a Leishmania amastigote-specific protein, member of the super-oxygenase family, against visceral leishmaniasis. Plos Neglected Tropical Diseases. v.7, p.e2148. (2013).